KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Goodwill & Intangibles (2016 - 2023)

Historic Goodwill & Intangibles for Inovio Pharmaceuticals (INO) over the last 15 years, with Q2 2023 value amounting to $10.5 million.

  • Inovio Pharmaceuticals' Goodwill & Intangibles fell 1838.96% to $10.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.5 million, marking a year-over-year decrease of 1838.96%. This contributed to the annual value of $12.6 million for FY2022, which is 377.86% down from last year.
  • According to the latest figures from Q2 2023, Inovio Pharmaceuticals' Goodwill & Intangibles is $10.5 million, which was down 1838.96% from $12.6 million recorded in Q1 2023.
  • Inovio Pharmaceuticals' 5-year Goodwill & Intangibles high stood at $15.0 million for Q1 2019, and its period low was $10.5 million during Q2 2023.
  • Its 5-year average for Goodwill & Intangibles is $13.4 million, with a median of $13.5 million in 2021.
  • Examining YoY changes over the last 5 years, Inovio Pharmaceuticals' Goodwill & Intangibles showed a top increase of 347.2% in 2023 and a maximum decrease of 1838.96% in 2023.
  • Over the past 5 years, Inovio Pharmaceuticals' Goodwill & Intangibles (Quarter) stood at $14.2 million in 2019, then decreased by 3.85% to $13.7 million in 2020, then fell by 3.81% to $13.1 million in 2021, then dropped by 3.78% to $12.6 million in 2022, then decreased by 16.85% to $10.5 million in 2023.
  • Its Goodwill & Intangibles stands at $10.5 million for Q2 2023, versus $12.6 million for Q1 2023 and $12.6 million for Q4 2022.